

## Prof. Burak ŞAKAR

### Personal Information

Office Phone: [+90 212 585 0007](tel:+902125850007)

Email: [bsakar@istanbul.edu.tr](mailto:bsakar@istanbul.edu.tr)

Web: <http://aves.istanbul.edu.tr/bsakar/>

### International Researcher IDs

ORCID: 0000-0003-3744-7044

Publons / Web Of Science ResearcherID: AAT-1485-2020

Yoksis Researcher ID: 167382

### Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.**  
Dogan I, Tastekin D., Karabulut S., Sakar B.  
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.3, 2021 (SCI-Expanded)
- II. **Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy**  
Aykan N. F., Yildiz I., Sen F., Kilic L., Keskin S., Ciftci R., Karabulut S., Sakar B., Disci R.  
MEDICAL ONCOLOGY, vol.30, no.3, 2013 (SCI-Expanded)
- III. **A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma**  
Saglam S., Aykan N. F., ŞAKAR B., GÜLLÜOĞLU M., Balik E., Karanlik H.  
JOURNAL OF GASTROINTESTINAL ONCOLOGY, vol.2, no.1, pp.19-26, 2011 (SCI-Expanded)
- IV. **Clinical outcome of rhabdomyosarcoma in adolescent and adult patients: Single center experience from Turkey**  
Ustuner Z., Basaran M., Dizdar Y., Agaoglu F. Y., Bilgic B., Sakar B., Basaran G. A., Darendeliler E., Ozger H., Onat H., et al.  
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol.213, no.3, pp.221-229, 2007 (SCI-Expanded)
- V. **A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas**  
Basaran M., Bavbek E. S., Saglam S., Eralp L., Sakar B., Atalar A. C., Bilgic B., Ozger H., Onat H.  
ONCOLOGY, vol.72, pp.255-260, 2007 (SCI-Expanded)
- VI. **The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients.**  
TAS F., USTUNER Z., CAN G., ERALP Y., CAMLICA H., BASARAN M., KARAGOL H., SAKAR B., Disci R., TOPUZ E.  
Acta oncologica (Stockholm, Sweden), vol.44, no.2, pp.161-7, 2005 (SCI-Expanded)
- VII. **Ewing's sarcoma of the axial system in patients older than 15 years: Dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment**  
Argon A., Basaran M., Yaman F., Dizdar Y., Sakar B., Camlica H., Bavbek S. E., Ozger H., Darendeliler E., Onat H.  
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.34, no.11, pp.667-672, 2004 (SCI-Expanded)
- VIII. **Clinicopathologic factors influencing survival of patients with bile duct and gallbladder carcinoma**  
Sakar B., Basaran M., Gumus M., Yazar A., Argon A., Aykan N. F.  
ANNALS OF ONCOLOGY, vol.15, pp.243-244, 2004 (SCI-Expanded)
- IX. **Colorectal cancer in young patients: Characteristics and outcome**

Alici S., Aykan N., ŞAKAR B., Bulutlar G., Kaytan E., Topuz E.

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol.199, no.2, pp.85-93, 2003 (SCI-Expanded)

- X. **A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer**

Başaran M., Bavbek S., Güllü İ., Demirelli F. H., Şakar B., Tenekeci N., Altun M., Yalçın S., Onat H.

JOURNAL OF CHEMOTHERAPY, vol.14, pp.207-213, 2002 (SCI-Expanded)

- XI. **Hypertrophic osteoarthropathy associated with docetaxel treatment.**

Tas F., Aydiner A., Tenekeci N., Karadeniz A. N., Sakar B., Topuz E.

Clinical oncology (Royal College of Radiologists (Great Britain)), vol.13, no.2, pp.145-6, 2001 (SCI-Expanded)

## Refereed Congress / Symposium Publications in Proceedings

- I. **Do serum nectin-2 levels have a prognostic effect in patients with colorectal cancer?**

Basaran M., KARABULUT S., KARABULUT M., GUNALDI M., ALIS H., Erturk K., Vatansever S., Sakar B., Aykan N. F.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- II. **Prognostic roles of serum NEDD9 levels in patients with gastric cancer.**

Karabulut S., Karabulut M., Alis H., Bozbey H. U., Sakar B., Vatansever S., Aykan N. F.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- III. **Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC)**

Keskin S., Sen F., AYDOGAN F., Ekenel M., Kilic L., SAGLAM S., Sakar B., Disci R., AYKAN F.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

- IV. **Opere lokal ileri mide kanserli hastalarda adjuvan kemoterapi ile kemoradyoterapinin etkinliğinin karşılaştırılması**

ORDU C., KILIC L., EKENEL M., ŞAKAR B., AYKAN F.

III. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 24 - 28 March 2010, pp.121

- V. **Chemoradiotherapy in the adjuvant treatment of gastric cancer**

Saglam E. K., Ozturk B., Baskaya S., Saglam S., Sakar B., Yamaner S., Balik E., Oral E. N., Kizir A., Aykan F.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.315-316

## Metrics

Publication: 16

Citation (WoS): 151

Citation (Scopus): 144

H-Index (WoS): 6

H-Index (Scopus): 5